Evidence for Two Modes of Synergistic Induction of Apoptosis by Mapatumumab and Oxaliplatin in Combination with Hyperthermia in Human Colon Cancer Cells

Xinxin Song1, Seog-Young Kim1, Yong J. Lee1,2*

1 Department of Surgery, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America, 2 Department of Pharmacology & Chemical Biology, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America

Abstract

Colorectal cancer is the third leading cause of cancer-related mortality in the world-- the main cause of death from colorectal cancer is hepatic metastases, which can be treated with isolated hepatic perfusion (IHP). Searching for the most clinically relevant approaches for treating colorectal metastatic disease by isolated hepatic perfusion (IHP), we developed the application of oxaliplatin concomitantly with hyperthermia and humanized death receptor 4 (DR4) antibody mapatumumab (Mapa), and investigated the molecular mechanisms of this multimodality treatment in human colon cancer cell lines CX-1 and HCT116 as well as human colon cancer stem cells Tu-12, Tu-21 and Tu-22. We showed here, in this study, that the synergistic effect of the multimodality treatment-induced apoptosis was caspase dependent and activated death signaling via both the extrinsic apoptotic pathway and the intrinsic pathway. Death signaling was activated by c-Jun N-terminal kinase (JNK) signaling which led to Bcl-xL phosphorylation at serine 62, decreasing the anti-apoptotic activity of Bcl-xL, which contributed to the intrinsic pathway. The downregulation of cellular FLICE inhibitory protein long isoform (c-FLIPL) in the extrinsic pathway was accomplished through ubiquitination at lysine residue (K) 195 and protein synthesis inhibition. Overexpression of c-FLIPL mutant (K195R) and Bcl-xL mutant (S62A) completely abrogated the synergistic effect. The successful outcome of this study supports the application of multimodality strategy to patients with colorectal hepatic metastases who fail to respond to standard chemoradiotherapy that predominantly targets the mitochondrial apoptotic pathway.

Introduction

Colorectal cancer, which causes approximately 10% of cancer deaths in the United States, is the third leading cause of cancer-related mortality in the world; death usually results from uncontrolled metastatic disease. Unfortunately, only 10-15% of initial colorectal liver metastases are considered resectable [1,2]. The unresectable cases of liver metastatic disease can be treated with isolated hepatic perfusion (IHP), which involves a method of complete vascular isolation of the liver to allow for multimodality treatment of liver tumors [3–6]. Mapatumumab (Mapa) is a fully human IgG1 agonistic monoclonal antibody which exclusively targets and activates death receptor 4 (DR4) with high specificity and affinity [7–9]. Briefly, Mapa binds to the cell surface of DR4 and triggers the extrinsic apoptotic pathway, mainly through the activation of the pro-apoptotic initiator caspase-8. However, phase II trials showed little or no clinical activity of single-agent Mapa in patients with advanced refractory colorectal cancer or non-small cell lung cancer [10,11]. Several possible molecular mechanisms have been suggested including mutation/defects in death receptors, the death-inducing signaling complex, caspsases, proapoptotic proteins or overexpression of anti-apoptotic molecules [12–14]. Thus, there is a continuing and significant need to develop applicable strategies to increase Mapa’s efficacy.

Hyperthermia, a treatment often used with isolated hepatic perfusion (IHP), maximizes tumor damage while preserving the surrounding normal tissue [5,6,15]. Oxaliplatin, a commonly used chemotherapy agent for colon cancer, is thought to trigger cell death mainly by inducing platinum-DNA adduct [3,16–18]. We previously developed a multimodality treatment...
using oxaliplatin pretreatment in combination with Mapa and hyperthermia to treat human colon cancer [19]. However, IHP delivering high doses of chemotherapy or biologic therapy regionally requires a standard operative technique, continuous intraoperative leak monitoring, and an external veno-veno bypass circuit [20]. Thus oxaliplatin pretreatment is not achievable in the procedure of the IHP in clinics, and all components of the multimodality procedure need to be performed simultaneously.

In this study, we investigated the therapeutic potential of the clinically relevant multimodality treatment schedule oxaliplatin and hyperthermia in combination with Mapa on human colon cancer cell lines and colon cancer stem cells. We report here that the multimodality treatment can sensitize human colon cancer cells to Mapa-induced apoptosis by multiple molecular mechanisms of action via both the intrinsic apoptotic pathway and the extrinsic pathway.

Materials and Methods

Cell cultures

Human colorectal carcinoma CX-1 cells, which were obtained from Dr. J.M. Jessup (National Institutes of Health) [21], were cultured in RPMI-1640 medium (Gibco BRL) containing 10% fetal bovine serum (HyClone). The human colorectal carcinoma HCT116 cell lines kindly provided by Dr. B. Vogelstein (Johns Hopkins University) were cultured in McCoy’s 5A medium (Gibco-BRL) containing 10% fetal bovine serum [22]. Human colon cancer stem cells, Tu-22, Tu-12 and Tu-21 [23], were established by Dr. E. Lagasse (University of Pittsburgh) and cultured in DMEM/F12 medium (Gibco BRL) containing 0.5% fetal bovine serum (HyClone) and 1% insulin, transferrin, and selenium (I.T.S, Fisher Scientific). All the cells were kept in a 37°C humidified incubator with 5% CO₂.

Reagents and antibodies

Oxaliplatin, MG132, cycloheximide (CHX) and protease inhibitor cocktail were obtained from Sigma Chemical Co. Mapatumumab (Mapa) was from Human Genome Sciences (Rockville, MD, USA). JNK inhibitor (SP6001125) and G418 were from Calbiochem. Anti-Flag, anti-caspase 8, anti-caspase 9, anti-caspase 3, anti-ubiquitin, anti-PARP, anti-phosphorylated JNK/JNK and anti-Bcl-xL antibody were from Cell Signaling. Anti-p-Bcl-xL (S62) antibody was from Chemicon/Millipore. Anti-FLIP antibody (NF6) was from Enzo Life Sciences. Anti-actin antibody was from Santa Cruz. Anti-FLIP antibody was from Cell Signaling. Anti-Flag antibody was from Sigma Chemical Co. Anti-p-Bcl-xL (S62) antibody was from Chemicon/Millipore. Anti-FLIP antibody was from Enzo Life Sciences. Anti-actin antibody was from Santa Cruz.

Transient transfection and stable transfection

For transient transfection, cells were transfected with Lipofectamine 2000 (Invitrogen), and were treated 48 h after transfection. For stable transfection, cells stably overexpressing HA-Bcl-xL wild-type (WT) or mutant types were prepared by transfecting CX-1 cells with HA-Bcl-xL-WT, HA-Bcl-xL-S62A (Ser62Ala), and HA-Bcl-xL-S62D (Ser62Asp) and maintained in 500 µg/ml G418. CX-1-Bcl-xL S62A cells were transfected with pLenti-Flag-FLIP, and stable clones were selected with G418. Pools of 3 clones were used in the experiment.

MTS

3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, MTS) assays

MTS studies were carried out using the Promega CellTiter 96 AQueous One Solution Cell Proliferation Assay (Promega). CX-1 cells were grown in tissue culture-coated 96-well plates and treated as described in Results. Cells were then treated with the MTS/phosphinothricin methosulfate solution for 1 h at 37°C. Absorbance at 490 nm was determined using an enzyme-linked immunosorbent assay plate reader.

Annexin V binding

Cells were heated in the absence or presence of Mapa and harvested by trypsinization, washed with serum-free medium, and suspended in binding buffer (Annexin V-FITC Staining Kit, PharMingen). This cell suspension was stained with mouse anti-human Annexin V antibody and PI and immediately analyzed by flow cytometry.

Quantitative reverse transcription-polymerase chain reaction (RT-PCR) analysis

Total RNA was extracted and purified from cultured cells using the RNeasy Mini Kit (Qiagen, Valencia, CA), according to the manufacturer’s instructions. The RNA was quantified by determining absorbance at 260 nm. Two µg of total RNA from each sample was reverse transcribed into cDNA using the High-Capacity cDNA Reverse Transcription Kit (Life Technologies, Inc.) in a volume of 20 µl. Quantitative PCR (qPCR) was carried out using Applied Biosystems inventoried TaqMan assays (20X Primer Probe mix) corresponding to CASP8 and FADD-like apoptosis regulator (CFLAR; assay ID Hs00153439_m1), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH; assay ID Hs00265197_m1). All reactions were carried out with 2 X TaqMan Universal PCR Master Mix (Applied Biosystems) on an Applied Biosystems StepOne Plus Real-Time PCR System according to standard protocols.

Immunoprecipitation

Briefly, cells were lysed in CHAPS lysis buffer with protease inhibitor cocktail (Calbiochem). 0.5-1 mg of lysate was incubated with 1.5 µg of anti-Flag/ubiquitin antibody or rabbit IgG (Santa Cruz) at 4°C overnight, followed by the addition of protein A-agarose beads (Santa Cruz) and rotation at room temperature for 2 h followed by immunoblot analysis.
Immunoblot analysis

Cells were lysed with Laemmli lysis buffer and boiled for 10 min. Protein content was measured with BCA Protein Assay Reagent (Pierce, Rockford, IL, USA), separated by SDS-PAGE and electrophoretically transferred to nitrocellulose membrane. The nitrocellulose membrane was blocked with 5% nonfat dry milk in PBS-Tween-20 (0.1% v/v) for 1 h and incubated with primary antibody at room temperature for 2 h. Horseradish peroxidase conjugated anti-rabbit or anti-mouse IgG was used as the secondary antibody. Immunoreactive protein was visualized by the chemiluminescence protocol (ECL, Amersham, Arlington Heights, IL, USA). The densities of bands between two groups were assessed using the Student’s t test.

Site-directed mutagenesis

Lys 106 to Arg (K106R) and K195R mutations of the plasmid pCR3.V64-Met-Flag-FLIP, which was a gift from Dr. Jurg Tschopp (University of Lausanne), were introduced into the c-FLIP gene using fully complementary mutagenic primers (QuickChange site-directed mutagenesis kit from Agilent Technologies). The following mutagenizing oligonucleotides were used: sense 5'-GAGATTTGCTGAGATTGATAGATCTG-ATGTGTCCCTATTAAT-3' and antisense 5'-ATTAATGAGACACATCAGATCTAT-CCAAATCCTCAACATCTC-3' for K106R mutant, sense 5'-CAAGCAGCAATCCA-AAAGAATCTCAGGATCTTCAAAT-3' and antisense 5'-ATTTGAAGGATCCCTGAG-ACTCTTTTGGATTGCTGCTTG-3' for K195R mutant. Mutants were confirmed by sequence analysis.

Results

The multimodality treatment of oxaliplatin/Mapa/hyperthermia activates both intrinsic and extrinsic pathways in human colon cancer cells

In this study, we attempted to develop clinically relevant multimodality therapy for colorectal metastatic disease which can be treated by IHP. The cell lines used include: human colorectal metastatic carcinoma HCT116 and CX-1 cells, and human colon cancer stem cells, Tu-12, Tu-21 and Tu-22, which were established by Dr. E. Lagasse (University of Pittsburgh) from the liver of metastatic colon cancer patients and cultured within the passages 10-30 [23]. Cancer stem cells (CSC) are able to self-renew, are tumorigenic, and are capable of producing the heterogeneous lineages of cancer cells that comprise the tumor. CSC should not only be affiliated with tumor initiation and growth, but are likely to be responsible for metastasis as well [24,25]. To investigate the effect of the multimodality treatment of oxaliplatin/Mapa/hyperthermia-induced cytotoxicity, cell viability was determined by MTS assay. As shown in Figure 1A and 1B, synergistic effect was observed in oxaliplatin/Mapa/hyperthermia compared with any other single treatment or bi-treatment in both cell lines (P < 0.01). Figure 1C clearly shows that synergistic induction of apoptotic death occurred during treatment with oxaliplatin/Mapa/hyperthermia. Similar results were obtained in human colon cancer stem cells Tu-12, Tu-21 and Tu-22 (Figure 1F). These synergistic effects were due to an increase in the activation of caspases (Figure 1D). Figure 1D shows that 100 ng/ml Mapa resulted in a small amount of caspase 8 and 3 activation, and thus PARP cleavage (the hallmark feature of apoptosis). Interestingly, hyperthermia promoted the activation of caspase 8, while oxaliplatin promoted caspase 9 activation. Moreover, the synergistic effect of the multimodality treatment was blocked by Z-IETD-FMK (caspase 8 inhibitor), Z-LEHD-FMK (caspase 9 inhibitor), and Z-DEVD-FMK (caspase 3 inhibitor) in both cell lines (Figure 1E), indicating that both pathways played an important role in the synergistic effect of the multimodality treatment.

Dose responses of oxaliplatin and hyperthermia on Mapa-induced apoptosis

We observed that as the doses of Mapa and oxaliplatin increased, caspase 8/9/3 activation and PARP cleavage were enhanced, indicating that the synergistic effect of the multimodality treatment-induced apoptosis was dose dependent (Figure 2A). Furthermore, our results suggest that both the intrinsic and extrinsic apoptotic pathways were involved in the synergistic effect of the multimodality treatment. Similar data was obtained in HCT116 cells (Figure 2B).

Multimodality treatment-induced JNK activation, Bcl-xL phosphorylation and reduction in c-FLIP, level

To further understand the mechanisms of how the intrinsic and extrinsic pathways were involved in the multimodality treatment-induced apoptosis, we examined Bcl-xL as well as c-FLIP. Figure 2C shows that there was no change in the amount of Bcl-xL protein, but the phosphorylation of Bcl-xL dramatically
Figure 1. Effect of oxaliplatin and hyperthermia on Mapa-induced cytotoxicity and apoptosis. (A, B) CX-1 and HCT116 cells were exposed to normothermic or hyperthermic (42°C) conditions for 1 h in the presence/absence of Mapa and oxaliplatin and then incubated for 23 h at 37°C in the presence/absence of Mapa and oxaliplatin. Cell viability was analyzed by MTS assay. Error bars represent SD from triplicate experiments. Asterisk ** represents a statistically significant difference (P <0.01). (C) CX-1 cells were exposed to hyperthermia (42°C) for 1 h in the presence/absence of Mapa and oxaliplatin and then incubated for 3 h at 37°C in the presence/absence of Mapa and oxaliplatin. After treatment, cells were stained with fluorescein isothiocyanate (FITC)-Annexin V and propidium iodide (PI). Apoptosis was detected by the flow cytometric assay. (D) After treatment, the cleavage of caspase 8, caspase 9, caspase 3, or PARP was detected by immunoblotting. Actin was used to confirm the equal amount of proteins loaded in each lane. (E) CX-1 and HCT116 cells were treated with or without 20 µM Z-IETD-FMK (caspase 8 inhibitor), Z-LEHD-FMK (caspase 9 inhibitor), and Z-DEVD-FMK (caspase 3 inhibitor) for 60 min followed by oxaliplatin/Mapa/hyperthermia and the cleavage of PARP was detected by immunoblotting. (F) Human colon cancer stem cells, Tu-12, Tu-21 and Tu-22, were exposed to normothermic or hyperthermic (42°C) conditions for 1 h in the presence/absence of Mapa and oxaliplatin at the indicated concentration and then incubated for 23 h at 37°C in the presence/absence of Mapa and oxaliplatin. PARP was detected by immunoblotting. Actin was used as loading control.

doi: 10.1371/journal.pone.0073654.g001
increased, accompanied by JNK phosphorylation. In addition, the level of c-FLIP_L significantly decreased during the multimodality treatment in CX-1 cells. Figure 2D demonstrates that JNK was activated and Bcl-xL was phosphorylated at serine 62 in a dose-dependent manner in CX-1 cells. Interestingly, the level of c-FLIP_L dramatically decreased when oxaliplatin was combined with hyperthermia. Similar data was obtained in HCT116 cells (Figure 2E).
We observed that the effect of the multimodality treatment increased as time progressed in CX-1 (Figure 3A) and HCT116 cells (Figure 3B). JNK activation reached maximum at 4 h after the initial treatment and gradually decreased during the multimodality treatment. Data from immunoblot and imaging gel analyses show that Bcl-xL phosphorylation reached the peak around 12 h after the treatment indicating that JNK activation was an early event and might regulate the Bcl-xL phosphorylation. In CX-1 cells the level of c-FLIP dramatically decreased at 4 h after the treatment of oxaliplatin combined with hyperthermia, while in HT116 cells, it reached minimum 24 h after the treatment.

The requirement of JNK activation and Bcl-xL phosphorylation in the multimodality treatment-induced apoptosis

JNK inhibitor SP6001125 partially reduced oxaliplatin/Mapa/ hyperthermia-induced PARP cleavage in CX-1 cells, indicating that the JNK pathway was crucial for multimodality treatment-induced apoptosis (Figure 4A). Noticeably, SP6001125 highly reduced the level of Bcl-xL phosphorylation in CX-1 cells, which provides strong evidence that multimodality treatment-induced Bcl-xL phosphorylation requires JNK activation. Zhao et al. reported that JNK activation mediates c-FLIP downregulation [26]. This possibility was examined in Figure 4A. We observed that no restoration of c-FLIP occurred during treatment with SP6001125. This observation was consistent with other researchers’ reports [27,28].

To evaluate the effect of Bcl-xL phosphorylation at Ser62 on its anti-apoptotic activity, we established CX-1-derived cell lines stably overexpressing wild-type Bcl-xL (Bcl-xL-WT), Ser62Ala phospho-defective Bcl-xL mutant (Bcl-xL-S62A), Ser62Asp phospho-mimic Bcl-xL mutant (Bcl-xL-S62D), or the corresponding empty vector (pcDNA). As expected, overexpression of Bcl-xL-WT prevented oxaliplatin/Mapa/ hyperthermia-induced PARP cleavage. Interestingly, overexpression of Bcl-xL-S62D enhanced PARP cleavage, whereas that of Bcl-xL-S62A inhibited PARP cleavage (Figure 4B). These data suggest that the level of Bcl-xL and its phosphorylation at S62 play an important role in the multimodality-induced apoptosis.

Reduction in c-FLIP<sub>L</sub> level following hyperthermia and oxaliplatin in CX-1 cells

c-FLIP is the major inhibitor of the extrinsic apoptotic pathway through inhibition of caspase-8 activation, and we observed that the level of c-FLIP<sub>L</sub> was reduced after hyperthermia at 42°C for 1 h in CX-1 cells as shown in Figure 5A. However, c-FLIP<sub>L</sub> was restored to the normal level after 3 h incubation at 37°C which was consistent with our previous paper [24]. Oxaliplatin (10 µg/ml, 4h) alone didn’t reduce the level of c-FLIP<sub>L</sub>. Interestingly, the level of c-FLIP<sub>L</sub> was maintained at a reduced level when hyperthermia combined with oxaliplatin.

Quantitative RT-PCR showed that no significant inhibition of c-FLIP expression at the mRNA level was evident after hyperthermia, oxaliplatin, or the combination (Figure 5B). We observed in Figure 5C that 25% of protein synthesis was inhibited in hyperthermia, whereas there was 46% protein synthesis inhibition in oxaliplatin combined with hyperthermia. Figure 5D shows that reduction of c-FLIP<sub>L</sub> level by 42°C for 1 h heating alone was more than that by 30 µg of cycloheximide
which inhibits protein synthesis by 99% [28]. These results suggest that protein synthesis inhibition alone is not a major factor for downregulation of FLIP\textsubscript{L} by hyperthermia. Remarkably, c-FLIP\textsubscript{L} was recovered during 3 h of normothermic condition, indicating that c-FLIP\textsubscript{L} was resynthesized. However, the recovery was delayed by treatment with hyperthermia and oxaliplatin, as protein synthesis was significantly inhibited.

Figure 5E shows that the ubiquitination of endogenous c-FLIP\textsubscript{L} increased upon hyperthermia treatments. Moreover, proteasome inhibitor MG132 blocked the degradation of c-FLIP\textsubscript{L}, confirming the existence of proteasomal-mediated degradation of the protein after hyperthermia. The online software UbPred, which predicts protein ubiquitination sites, showed that lysine 106 and 195 had the highest scores. We replaced 106 and 195 lysine with arginine and tested the stability of the full-length c-FLIP\textsubscript{L} carrying the resulting point mutation. As shown in Figure 5F, in the transfection group, c-FLIP\textsubscript{L} K106R was easily degraded when subjected to hyperthermia while K195R was refractory to degradation by hyperthermia. Figure 5G confirms that c-FLIP\textsubscript{L} wild-type (WT) was efficiently ubiquitinated but not the K195R mutant, which was found virtually without ubiquitination. We observed that c-FLIP\textsubscript{L} K195R expressing cells were the most resistant to the multimodality treatment-induced apoptotic cell death (Figure 5H and 5I). These results suggest that the transient hyperthermia-mediated degradation of c-FLIP\textsubscript{L} involved ubiquitination of K195, and K195R mutant conferred resistance against the multimodality treatment-induced apoptotic death.

Abrogation of the synergistic effect by overexpression of c-FLIP\textsubscript{L} K195R and Bcl-xL-S62A in CX-1 and HCT116 cells

Finally, we compared the effect of the multimodality treatment in CX-1 and HCT116 cells overexpressed with c-FLIP\textsubscript{L} WT, Bcl-xL-S62A, Bcl-xL-S62A + c-FLIP\textsubscript{L} WT (Figure 6A and 6B) and c-FLIP\textsubscript{L} K195R, Bcl-xL-S62A, Bcl-xL-S62A + c-FLIP\textsubscript{L} K195R (Figure 6C and 6D). We observed that c-FLIP\textsubscript{L} WT/K195R or Bcl-xL-S62A partially blocked the effect of the multimodality treatment. Of note, the multimodality treatment-induced apoptosis was almost completely blocked by overexpression of both c-FLIP\textsubscript{L} WT/K195R and Bcl-xL-S62A (Figure 6A and 6C), indicating c-FLIP\textsubscript{L} and Bcl-xL were independent factors contributing to the synergistic effect of the multimodality treatment. Similar results were obtained in cell viability assay (Figure 6B and 6D). Our results suggest that (a) reduction in c-FLIP\textsubscript{L} level and (b) Bcl-xL phosphorylation at Ser62 are both responsible for the synergistic induction of apoptosis of the clinically relevant multimodality treatment.

Discussion

Our laboratory has focused on identifying strategies and mechanisms for thermal sensitization in an attempt to improve the clinical efficacy of IHP [19,29–31]. We previously developed the multimodality treatment (oxaliplatin pretreatment + Mapa + hyperthermia) for colorectal cancer hepatic metastases. In this study, we investigated the efficacy and the underlying mechanisms of the more clinically relevant simultaneous treatment schedule of oxaliplatin + Mapa + hyperthermia-induced apoptosis and proposed that (a) reduction in c-FLIP\textsubscript{L} level and (b) Bcl-xL phosphorylation at Ser62 are both responsible for the synergistic induction of apoptosis of the clinically relevant multimodality treatment.

First, we compared the efficacy of the pretreatment of oxaliplatin followed by Mapa and hyperthermia to that of simultaneous treatment of oxaliplatin, Mapa and hyperthermia (Figure S1). We observed that oxaliplatin pretreatment resulted in maximum apoptotic cell death which was consistent with our previous paper [19]. Notably, synergistic effect was still observed in the more clinically relevant multimodality treatment schedule (cotreatment with oxaliplatin). Assays of caspase inhibitors confirmed that both pathways played an important role in the synergistic effect of the multimodality treatment. It is known that combinatorial drug effects are complex, even for relatively specific drugs [32]. The goal of this study is to reveal the key molecules in mediating the synergistic induction of
apoptosis and how these molecules rewired the apoptotic signaling networks.

Bcl-xL is a pro-survival member of the Bcl-2 family that plays indispensable roles in the intrinsic pathway. It is overexpressed in many malignant tumors including colorectal cancer. The status of Bcl-xL protein expression might be an independent prognostic marker for colorectal cancer patients [33]. Bcl-xL undergoes phosphorylation in response to microtubule inhibitors and other apoptotic stimuli [17,34]. Our study revealed that the oxaliplatin + Mapa + hyperthermia clinically relevant schedule synergistically induced Bcl-xL phosphorylation. We also observed that Bcl-xL phosphorylation

Figure 5. Reduction in c-FLIP\textsubscript{L} level following hyperthermia and oxaliplatin in CX-1 cells. (A) Cells were exposed to 37°C or 42°C for 1 h in the presence/absence of 10 µg/ml oxaliplatin and then harvested immediately or 3 h after incubation at 37°C. c-FLIP\textsubscript{L} was examined by Western blot analysis. (B) Cells were exposed to 37°C or 42°C for 1 h in the presence/absence of 10 µg/ml oxaliplatin and then incubated for 3 h at 37°C. Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was performed to measure relative c-FLIP\textsubscript{L} mRNA level. The bar graph represents mean values (+SD) from triplicate experiments. (C) Cells were exposed to 37°C or 42°C for 1 h in the presence/absence of 10 µg/ml oxaliplatin and then incubated for 3 h at 37°C. Protein synthesis was measured by \textsuperscript{35}S Methionine incorporation. (D) Cells were treated with 30 µg/ml CHX, or exposed to hyperthermia in the presence or absence of CHX. The levels of c-FLIP\textsubscript{L} and loading control actin were measured by Western blot analysis. (E) Cells were exposed to hyperthermia for 30 or 60 min in the presence/absence of MG132. Lysate samples were immunoprecipitated with anti-ubiquitin antibody and protein G-Sepharose. The ubiquitinated FLIP was detected by Western blot with anti-FLIP antibody. (F) Cells were transiently transfected with 4 µg plasmid containing mock, K106R (106 lysine residue was replaced with arginine), K195R, or wild-type (WT) c-FLIP\textsubscript{L}. After 48 h incubation, cells were exposed to hyperthermia at 42°C for 1 h. The level of c-FLIP\textsubscript{L} was detected by anti-FLIP antibody. Actin was used as an internal control. (G) Cells were transiently transfected with Flag-tagged c-FLIP\textsubscript{L} WT or K195R plasmid; 48 h later, cells were subjected to hyperthermia at 42°C for 1 h. The levels of ubiquitinylated c-FLIP\textsubscript{L} were detected by IP with anti-Flag antibody followed by Western blot using anti-ubiquitin antibody. The presence of transfectant c-FLIP\textsubscript{L} in the lysates was verified by Western blot. Actin was shown as an internal standard. (H) Cells were transiently transfected with Flag-tagged c-FLIP\textsubscript{L} WT, K106R, or K195R plasmid; 48 h later, cells were heated at 42°C for 1 h in the presence/absence of Mapa (100 ng/ml) and oxaliplatin (10 µg/ml) and then incubated at 37°C for 3 h. Lysates containing equal amounts of protein were immunoblotted with anti-PARP and anti-FLIP antibody. Actin was shown as an internal standard. (I) Cells were transiently transfected with c-FLIP\textsubscript{L} WT, K106R, or K195R plasmid; 48 h later, cells were heated at 42°C for 1 h in the absence or presence of Mapa (100 ng/ml) and oxaliplatin (10 µg/ml), and then incubated for 24 h at 37°C. Cell viability was analyzed by MTS assay. Error bars represent SD from triplicate experiments. Asterisk * represents a statistically significant difference (P <0.05).
doi: 10.1371/journal.pone.0073654.g005
required activated JNK, which can recognize a proline residue on the carboxyl side of the phospho-acceptor [35]. Our data highlighted the role of phosphorylation at Ser62, which antagonized the anti-apoptotic function, probably due to a changed interaction between Bax/phospho-mimic Bcl-xL-S62D and Bax/Bcl-xL-S62A. However, our data also implied Bcl-xL phosphorylation is crucial but not sufficient to the contribution of the synergistic effect of the multimodality treatment, indicating that other mechanisms should be identified.

c-FLIP is the major inhibitor of the extrinsic apoptotic pathway through inhibition of caspase-8 activation and processing at the death-inducing signaling complex (DISC) [36–40]. Differential splicing gives rise to long (c-FLIP_L) and short (c-FLIP_S) forms of c-FLIP. Both c-FLIP splice variants bind to FADD within the DISC. They compete with caspase 8 for DISC association and can form heteromeric complexes, thereby inhibiting apoptosis [37,41]. c-FLIP_L, which is the most abundant isoform in many cancer cell lines, is a key regulator of colorectal cancer cell death and associated with a poor prognosis in colorectal cancer patients [39,42,43]. Given the central role of c-FLIP_L in extrinsic apoptotic death in colon cancer cells, we investigated in depth the mechanism of FLIP_L down-regulation in the multimodality treatment.

It is reported that c-FLIP is regulated at the transcriptional, translational level or through protein degradation [44–47]. We observed that the level of c-FLIP_L was reduced after hyperthermia. Quantitative RT-PCR showed that the decrease of c-FLIP level was not due to transcriptional regulation. FLIP_L was dramatically reduced in the presence of the protein synthesis inhibitor cycloheximide, indicating that c-FLIP_L was degraded during hyperthermia. Ubiquitination assay showed that endogenous c-FLIP_L underwent proteosomal-mediated degradation after hyperthermia. However, c-FLIP_L was a fast-turnover protein and resynthesized after incubation at 37°C.

Figure 6. Protection from multimodality treatment-induced apoptosis by overexpression of c-FLIP_L WT/K195R and Bcl-xL-S62A in CX-1 or HCT116 cells. (A) CX-1 cells stably overexpressed with pcDNA, c-FLIP_L WT, Bcl-xL-S62A and c-FLIP_L WT + Bcl-xL-S62A, and three stable clones were pooled, and cells were heated at 42°C for 1 h in the presence/absence of Mapa (10 ng/ml) and oxaliplatin (10 µg/ml) and then incubated at 37°C for 3 h. The cleavage of PARP, and the level of c-FLIP_L and Bcl-xL were detected by Western blot analysis. (B) Cell viability was analyzed by MTS assay 24 h after treatment. Error bars represent SD from triplicate experiments. Asterisk ** represents a statistically significant difference (P <0.01). (C) HCT116 cells were transiently transfected with equal amount of plasmid containing mock, c-FLIP_L K195R, Bcl-xL-S62A and c-FLIP_L K195R + Bcl-xL-S62A. After 48 h incubation, cells were heated at 42°C for 1 h in the presence/absence of Mapa (10 ng/ml) and oxaliplatin (10 µg/ml) and then incubated at 37°C for 3 h. The cleavage of PARP, and the level of c-FLIP_L and Bcl-xL were detected by Western blot analysis. (D) Cell viability was analyzed by MTS assay 24 h after treatment. Error bars represent SD from triplicate experiments. Asterisk * represents a statistically significant difference (P <0.05).

do: 10.1371/journal.pone.0073654.g006
Interestingly, the level of c-FLIP\textsubscript{p} remained decreased when hyperthermia was combined with oxaliplatin. Protein synthesis assay showed 46% protein synthesis inhibition in oxaliplatin combined with hyperthermia; thus the decrease of c-FLIP\textsubscript{p} was due to the degradation through c-FLIP\textsubscript{p} ubiquitination by hyperthermia and delay of c-FLIP\textsubscript{p} restoration through protein synthesis inhibition by oxaliplatin combined with hyperthermia. We also found that c-FLIP\textsubscript{p} K195R was refractory to degradation by hyperthermia and prevented the multimodality treatment-induced apoptotic cell death.

Our results showed that c-FLIP\textsubscript{p} WT/K195R and Bcl-xL-S62A were independent factors that blocked the synergistic effect of the clinically relevant multimodality treatment, indicating that two modes of synergistic induction of apoptosis were involved in the multimodality treatment. The levels of Bcl-xL/c-FLIP\textsubscript{p} may serve as biomarkers for multimodality treatment and prognosis. A high value of Bcl-xL/c-FLIP\textsubscript{p} signature in the tumor may predict less response to the chemotherapy and thus the multimodality treatment would be suggested in this situation. Indeed several researchers reported that the prognosis was reversely correlated to the value of Bcl-xL/c-FLIP\textsubscript{p} \cite{33,43,48,49}.

Taken together, we document here that the clinically relevant multimodality treatment oxaliplatin, Mapa and hyperthermia increased apoptosis signaling via both the intrinsic and extrinsic apoptotic pathways. Given the facts that hyperthermia has a favorable safety profile, oxaliplatin is a commonly used chemotherapeutic drug for colon cancers, and Mapa currently is undergoing clinical testing, this multimodality treatment has an excellent translational potential and should be considered for colorectal hepatic metastases treatment in clinics.

**Supporting Information**

Figure S1. Effect of pretreatment of oxaliplatin on multimodality-induced apoptosis. CX-1 cells were pretreated with oxaliplatin for various times (0 h-20 h) and exposed to normothermic or hyperthermic (42°C) conditions for 1 h in the presence/absence of Mapa and oxaliplatin and then incubated for 3 h at 37°C. After treatment, the cleavage of PARP was detected by immunoblotting. Actin was used as loading control. (TIF)

**Acknowledgements**

We thank Dr. Patrick Kaminker from Human Genome Sciences who provided us mapatumumab, Dr. Timothy C. Chambers who provided pBcl-xL-WT, pBcl-xL-S62A and pBcl-xL-S62D, Dr. Shi-Yong Sun who provided us pLent-Flag-FLIP\textsubscript{p}, and Dr. J. Tschopp who provided us with pCR3.V64-Met-Flag-FLIP\textsubscript{p}.

**Author Contributions**

Conceived and designed the experiments: YL XS. Performed the experiments: YL XS YL. Analyzed the data: YL XS. Contributed reagents/materials/analysis tools: YL XS. Wrote the manuscript: XS YL.

**References**

1. Ruers T, Bleichrodt RP (2002) Treatment of liver metastases, an update on the possibilities and results. Eur J Cancer 38: 1023-1033. doi:10.1016/S0959-8049(02)00059-X. PubMed: 11978527.

2. Jemal A, Bray F, Center MM, Ferlay J, Ward E et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90. doi:10.3322/caac.20087. PubMed: 21296855.

3. Zeh HJ 3rd, Brown CK, Holtzman MP, Egorin MJ, Holleran JL et al. (2009) A phase I study of hyperthermic isolated hepatic perfusion with oxaliplatin in the treatment of unresectable liver metastases from colorectal cancer. Ann Surg Oncol 16: 385-394. doi:10.1245/s10434-008-0179-5. PubMed: 19034580.

4. Alexander HR Jr., Libutti SK, Pingpank JF, Bartlett DL, Helsabeck C et al. (2005) Isolated hepatic perfusion for the treatment of patients with colorectal cancer liver metastases after inotocanec-based therapy. Ann Surg Oncol 12: 138-144. doi:10.1245/ASO.2005.05.003. PubMed: 15827794.

5. Vanghese S, Xu H, Bartlett D, Hughes M, Pingpank JF et al. (2010) Isolated hepatic perfusion with high-dose melphalan results in immediate alterations in tumor gene expression in patients with metastatic ocular melanoma. Ann Surg Oncol 17: 1870-1877. doi:10.1245/s10434-010-0996-2. PubMed: 20221901.

6. Hafström LR, Holmberg SB, Naredi PL, Lindnér PG, Bengtsson A et al. (1994) Isolated hyperthermic liver perfusion with chemotherapy for liver malignancy. Surg Oncol 3: 103-108. doi:10.1016/0960-7404(94)90005-1. PubMed: 7952389.

7. Mom CH, Verweij J, Oldenhsin CN, Gietema JA, Fox NL et al. (2009) Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in patients with refractory colorectal cancer. Br J Cancer 102: 506-512. doi:10.1038/sj.bjc.6605507. PubMed: 20068564.

8. Greco FA, Bonomi P, Crawford J, Kelly K, Oh Y et al. (2008) Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer. Lung Cancer 61: 82-90. doi:10.1016/j.lungcan.2007.12.011. PubMed: 18255187.

9. Vulfovich M, Saba N (2005) Technology evaluation: mapatumumab, Human Genome Sciences/GlaxoSmithKline/Takeda. Curr Opin Mol Ther 7: 502-510. PubMed: 16248286.

10. Trarbach T, Moehler M, Heinemann V, Köhne CH, Przyborek M et al. (2010) Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer. Br J Cancer 102: 506-512. doi:10.1038/sj.bjc.6605507. PubMed: 20068564.

11. Trarbach T, Moehler M, Heinemann V, Köhne CH, Przyborek M et al. (2010) Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer. Lung Cancer 61: 82-90. doi:10.1016/j.lungcan.2007.12.011. PubMed: 18255187.

12. Zhang L, Fang B (2005) Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 12: 228-237. doi:10.1038/sj.cgt.7000792. PubMed: 15550937.

13. Dimberg LY, Anderson CK, Camidge R, Behbakti K, Thorburn A et al. (2013) On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics. Oncogene 32: 1341-1350. doi:10.1038/onc.2012.164. PubMed: 22590613.

14. Mahalingam D, Oldenhsin CN, Szegedi E, Giles FJ, de Vries EG et al. (2011) Targeting TRAIL towards the clinic. Curr Drug Targets 12: 2079-2090. doi:10.2174/13894501179829357. PubMed: 21777191.

15. Hegewisch-Becker S, Gruber Y, Corovic A, Pichlmayer U, Atanackovic D et al. (2002) Whole-body hyperthermia (41.8 degrees C) combined with bimonthly oxaliplatin, high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer: a phase II study. Ann Oncol 13: 1197-1204. doi:10.1093/annonc/md216. PubMed: 12181242.

16. Raymond E, Favre S, Chaney S, Woynarowski J, Cvitkovic E (2002) Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Ther 1: 227-235. PubMed: 12467217.

17. El Fajou Z, Toscano F, Jacquemin G, Abello J, Scazzec JY et al. (2011) Oxaliplatin sensitizes human colon cancer cells to TRAIL.
Hyperthermia enhances mapatumumab-induced apoptotic death of colon cancer cells. Cell Death Dis 4: e577. doi:10.1038/cddis.2013.104. PubMed: 15204521.

Song X, Kim SY, Lee YJ (2012) The role of Bcl-xL in synergistic induction of apoptosis by mapatumumab and oxaliplatin in combination with hyperthermia on human colon cancer. Mol Cancer Res 10: 1567-1579. doi:10.1159/1541-7769.MCR-12-0209-T. PubMed: 23051936.

Lubutti SK, Barlett DL, Fraker DL, Alexander HR (2000) Technique and results of hyperthermic isolated hepatic perfusion with tumor necrosis factor and melphalan for the treatment of unresectable hepatic malignancies. J Am Coll Surg 191: 519-530. doi:10.1016/S1072-7515(00)70033-X. PubMed: 11085732.

Lee YJ, Galoforo SS, Battle P, Lee H, Corry PM et al. (2001) Replicating adenoviral vector-mediated transfer of a heat-inducible double suicide gene for gene therapy. Cancer Gene Ther 8: 397-404. doi:10.1038/sj.cgt.7000310. PubMed: 11498759.

Cummins JM, Kohli M, Rago C, Knizier KW, Vogelstein B et al. (2004) X-linked inhibitor of apoptosis protein (XIAP) is a nonredundant modifier of tumor necrosis factor-induced apoptosis-inducing ligand (TRAIL)-mediated apoptosis in human cancer cells. Cancer Res 64: 3006-3008. doi:10.1158/0008-5472.CAN-04-0046. PubMed: 15126334.

Odoux C, Fohrer H, Hoppo T, Guzik L, Stolz DB et al. (2008) A stochastic model for cancer stem cell origin in metastatic colon cancer. Cancer Res 68: 6902-6941. doi:10.1158/0008-5472.CAN-07-1779. PubMed: 18754707.

Gao W, Chen L, Ma Z, Du Z, Zhao Z et al. (2013) Isolation and Phenotypic Characterization of Colorectal Cancer Stem Cells with Organ-Specific Metastatic Potential. Gastroenterology. PubMed: 23747337.

Liu C, Xue H, Lu Y, Chi B (2012) Stem cell gene Girdin: a potential target for cancer therapy. Curr Cancer Drug Targets 11: 1547-1558. PubMed: 22174016.

Lin Y, Liu X, Yue P, Benbrook DM, Berlin KD et al. (2008) Involvement of c-FLIP: a key regulator of colorectal cancer cell death. Oncogene 27: 5070-5075. doi:10.1158/1078-0432.CCR-06-2547. PubMed: 17785559.

Mawji IA, Simpson CD, Gronda M, Williams MA, Hurren R et al. (2007) A chemical screen identifies anisomycin as an anoikis sensitizer that rewires apoptotic signaling networks. Cell 149: 780-794. doi:10.1016/j.cell.2012.03.031. PubMed: 22570283.

Song X, Zhao-Xia W, Cheng-Yu L, Xiao-Di L, Ming S et al. (2011) Prognostic significance of Bcl-xL gene expression in human colorectal cancer. Acta Histochem 113: 810-814. doi:10.1016/j.achis.2011.01.002. PubMed: 21277008.

Shi Y (2008) FLIP and the death effector domain family. Oncogene 27: 6216-6227. doi:10.1038/sj.onc.1209122. PubMed: 18931689.

Deitch EA, Ahearn LJ, Curley SA (2007) c-FLIP: a novel target for cancer therapy. Curr Cancer Drug Targets 7: 150-156. doi:10.1111/j.1365-2902.2007.01419.x. PubMed: 17559541.